Ioglunide: a new nonionic contrast medium for myelography and cisternography with reduced neurotoxicity.

R E Gonsette and L Liesenborghs

*AJNR Am J Neuroradiol* 1983, 4 (3) 304-305

http://www.ajnr.org/content/4/3/304

This information is current as of October 14, 2023.
Ioglunide: A New Nonionic Contrast Medium for Myelography and Cisternography with Reduced Neurotoxicity

R. E. Gonsette¹ and L. Liesenborghs²

Ioglunide, a new nonionic contrast medium, has attracted attention by its virtual absence of immediate or delayed effect on brain electrical activity in animal studies. After 126 myelographies or cisternographies with ioglunide, routine electroencephalograms (EEG) and brain potential frequency analyses were performed in 109 and 73 patients, respectively. EEG changes were noted in 3.7% of subjects. Moderate meningeal signs were present in 16% of subjects. No severe adverse reactions (psychogenic syndrome, asterixis, or hallucination) were observed. Ioglunide appears to represent a marked advance in neuroradiology in providing for the comfort of patients and the safety of the radiological procedures.

Ioglunide (fig. 1) is a nonionic contrast medium developed by Guerbet (Aulnay-sous-Bois, France) in 1976. At that time, preliminary animal experiments conducted in our laboratory demonstrated that the neurotoxicity of the new compound was very low. However, solutions available for use were unstable and more elaborate studies were postponed. In 1978, using the corticospinal evoked-potentials technique in monkeys, Hilal et al. [1] demonstrated that the neurotoxicity of ioglunide was lower than that of metrizamide. Recently we found that after pericerebral injection of iophylized ioglunide in the guinea pig, delayed electroencephalographic (EEG) changes detected by monitored EEG frequency analysis were less marked for ioglunide than for other contrast media [2]. Since further animal experiments indicated a reduced cellular toxicity and epileptogenic activity for ioglunide as well, it was decided to investigate the possibility of a better clinical tolerance in man.

Subjects and Methods

Ioglunide was injected intrathecally in 126 patients by lumbar or suboccipital puncture using a 22 gauge needle. The regions investigated and the number of patients in each category were as follows: lumbar, 38; thoracic plus cervical, 11; cervical, 41; basal cisterns, 33; ventricles, three. Myelography was performed using an iodine concentration of 280 mg I/ml and a volume of 5 ml for cervical and lumbar investigations and 10 ml for total myelographies. A concentration of 140 mg I/ml in a volume of 10 ml was used for computed tomographic (CT) investigations (cisternographies and cervical myelographies). The total dose of iodine was 1.4–2.8 g. No premedication was given. After all procedures, patients were asked to remain in bed with their head slightly elevated for 6 hr.

Follow-up neurologic examinations were performed at 8 hr, 24 hr, and 48 hr. Patients were questioned about the presence of any minor side effects as well as more severe adverse reactions (e.g., lapses of consciousness, hallucinations, memory disturbances, dysphasia). Routine EEG in 109 patients and EEG frequency analysis in 73 patients were performed before and 8 hr or 24 hr after the radiographic procedures.

Results

Symptoms of meningeal irritation occurring as side effects of ioglunide myelography were moderate. Sixteen (14%) of 126 patients reported headache, three reported nausea, and one reported vomiting. Muscular pain was reported by five patients. No clinical signs of spinal or cerebral dysfunction were reported or observed. Results of the EEG studies are shown in table 1. The incidence of altered EEG after intrathecal injection of ioglunide appears exceptionally low (3.7%) compared with other contrast media.

Discussion

The development of metrizamide for the opacification of peri­dural and pericerebral spaces represents a definite advancement in the field of contrast media. However, despite better tolerance and increased safety, sporadic unexpected adverse reactions have been reported (e.g., psychogenic syndromes, asterixis, speech disturbances). A recent prospective study by Hauge and Falkenberg [3] reported neuropsychologic reactions and other side effects after metrizamide myelography in 100 patients. Confusion and amnesia were observed in 6% and hallucinations in 4% of the patients. A recent publication by Vespignani et al. [4] reported transient but definite EEG disturbances after metrizamide administration in 30 (32.6%) of 92 patients. These data correspond well with our personal experience using metrizamide in myelography and cisternography.

We have found iopamidol, a more recently developed nonionic contrast medium, to be somewhat more epileptogenic than metrizamide in animal studies. This suggests that iopamidol does not represent a marked improvement over metrizamide. It is quite difficult to estimate human tolerance to this new compound, as its clinical use is still limited. However, epileptic seizures and psychogenic syndromes have already been reported, and EEG changes have been observed in 16.5%–30% of subjects [5–10].

¹ Department of Neurology, Clinique Saint-Pierre, Ottignies LLN 1340, Belgium. Address reprint requests to R. E. Gonsette.
² Department of Radiology, Clinique Saint-Pierre, Ottignies LLN 1340, Belgium.
Table 1: EEG Changes after Intrathecal Injection of Ioglunide

<table>
<thead>
<tr>
<th>Procedure: Region</th>
<th>Total Dose iodine (g)</th>
<th>No. Patients (n = 109)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Unchanged EEG</td>
</tr>
<tr>
<td>Lumbar</td>
<td>2-2.8</td>
<td>35</td>
</tr>
<tr>
<td>Thoracic</td>
<td>2.8</td>
<td>7</td>
</tr>
<tr>
<td>Cervical</td>
<td>1.4-2.8</td>
<td>31</td>
</tr>
<tr>
<td>Computed tomography:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervical</td>
<td>1.4</td>
<td>11</td>
</tr>
<tr>
<td>Basal cisterns</td>
<td>1.4</td>
<td>21</td>
</tr>
<tr>
<td>Total nos. (%)</td>
<td>105 (96.3)</td>
<td>4 (3.7)</td>
</tr>
</tbody>
</table>

Note.—EEG = electroencephalographic. Routine EEG examinations in 109 patients and EEG frequency analyses in 73 patients were performed 8 hr or 24 hr after radiographic procedures.

In at least 70% of our investigated cases, ioglunide came into contact with brain tissue during the examination. This represents a valuable clinical assessment of the neurotoxic effects of this new contrast medium. The results were encouraging. The minor side effects were similar to those experienced after diagnostic lumbar puncture. Severe adverse reactions, and in particular psychogenic syndromes, were never observed. The incidence of EEG changes (3.7%) is far lower than that observed after intrathecal injection of metrizamide or iopamidol (mean, 35%).

Despite the technical disadvantages in using a contrast medium that is dispensed as a lyophilized powder, we believe ioglunide represents a definite advancement for myelography and cisternography in consideration of the comfort of patients and the safety of the neuroradiologic procedures.

References